Литература.

Поставить закладку

1. Vardiman J.W., Thiele J., Arber D.A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes / Vardiman J.W., Thiele J., Arber D.A., et al. // Blood. - 2009. - Т.114. №5. - С.937-951.
2. Rollison D.E., Howlader N., Smith M.T., et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs / Rollison D.E., Howlader N., Smith M.T., et al. // Blood. - 2008. - Т.112. №1. - С.45-52.
3. Tefferi F. the history of myeloproliferative disorders: before and after Dameshek. Leykemia 2008; 22:3-13.
4. Jones, A.V. Cross et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders / A.V.Jones, S. Kreil, K. Zoi et al. // Blood. - 2005. - Vol.106 №6. - P.2162-2168.
5. Campbell P.J., Scott L.M., Buck G., et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study / Campbell P.J., Scott L.M., Buck G., et al. // The Lancet. - 2005. - Т.366. №9501. - С.1945-1953.
6. Tefferi A. Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2 V617F Era / Tefferi A. // ASH Education Program Book. - 2006. - Т.2006. №1. - С.240-245.
7. Vannucchi A.M., Pieri L. and Guglielmelli P. JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment / Vannucchi A.M., Pieri L. and Guglielmelli P. // Therapeutic Advances in Hematology. - 2011. - Т.2. №1. - С.21-32.
8. Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007;21:1960-1963.
9. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: A critical reappraisal. Leukemia 2008;22:1299-1307.
10. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood 2007;110:1092-1097
11. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol. 2005 Nov 20;23(33):8520-30.
12. Campbell PJ, Scott LM, Baxter EJ, Bench AJ, Green AR, Erber WN. Methods for the detection of the JAK2 V617F mutation in human myeloproliferative disorders. Methods Mol Med. 2006;125:253-64.
13. Pardanani A, Lasho TL, Finke CM, Tefferi A. Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis. Am J Hematol 2011;86:701-702.
14. Ohashi H, Arita K, Fukami S, et al. Two rare MPL gene mutations in patients with essential thrombocythemia. Int J Hematol 2009;90:431-432.
15. Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: Analysis of the PT-1 cohort. Blood 2008;112:141-149.
16. Ding J, Komatsu H, Wakita A, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 2004;103:4198-4200.
17. Liu K, Martini M, Rocca B, et al. Evidence for a founder effect of the MPLS505N mutation in eight Italian pedigrees with hereditary thrombocythemia. Haematologica 2009;94:1368-1374.
18. Pardanani A, Guglielmelli P, Lasho TL, et al. Primary myelofibrosis with or without mutant MPL: Comparison of survival and clinical features involving 603 patients. Leukemia 2011;25:1834-1839.
19. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood 2008;112:844-847.
20. Guglielmelli P, Pancrazzi A, Bergamaschi G, et al. Anaemia characterizes patients with myelofibrosis harbouring Mpl mutation. Br J Haematol 2007; 137:244-247.
21. Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: An international study of 891 patients. Blood 2011;117:5857-5859.
22. Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: The impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010;24:1574-1579.
23. Passamonti F, Elena C, Schnittger S, et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood 2011;117:2813-2816.
24. Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, Marfisi RM, Finazzi G, Guerini V, Fabris F, Randi ML, De Stefano V, Caberlon S,Tafuri A, Ruggeri M, Specchia G, Liso V, Rossi E, Pogliani E, Gugliotta L, Bosi A, Barbui T Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007 Aug 1;110(3):840-6. Epub 2007 Mar 22.
25. Klampfl T., Gisslinger H., Harutyunyan A.S. et.al. Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms.// N Engl J Med. 2013 Dec 10. [Epub ahead of print].
26. Nangalia J, Massie CE, Baxter EJ et.al. Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2.// N Engl J Med. 2013 Dec 10. [Epub ahead of print].
27. Tefferi A, Lasho TL, Abdel-Wahab O, et al. IDH1 and IDH2 mutation studies in1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010;24:1302-1309.
28. Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis, Leukemia 2009;23:905-911.
29. Brecqueville M, Rey J, Bertucci F, et al. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes Cancer 2012;51:743-755.
30. Stegelmann F, Bullinger L, Schlenk RF, et al. DNMT3A mutations in myeloproliferative neoplasms. Leukemia 2011;25:1217-1219
31. Guglielmelli P, Biamonte F, Score J, Hidalgo-Curtis C, Cervantes F, Maffioli M, Fanelli T, Ernst T, Winkelman N, Jones AV, Zoi K, Reiter A, Duncombe A, Villani L, Bosi A, Barosi G, Cross NC, Vannucchi AM EZH2 mutational status predicts poor survival in myelofibrosis. Blood. 2011 Nov 10;118(19):5227-34. doi: 10.1182/blood-2011-06-363424. Epub 2011 Sep 14.
32. Brecqueville M, Rey J, Bertucci F, et al. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes Cancer 2012;51:743-755.
33. Varricchio L., Mancini A. and Anna Rita Migliaccio. Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.// Expert Rev Hematol. Author manuscript; 2009; June 1. 2(3). PP.315-334].
34. Tefferi A., Pathogenesis of Myelofibrosis With Myeloid Metaplasia. Journal of Clinical Oncology, 2005. 23(33): p. 8520-8530.
35. Cho S.Y., M. Xu, J. Roboz, M. Lu, J. Mascarenhas, and R. Hoffman, The Effect of CXCL12 Processing on CD34+ Cell Migration in Myeloproliferative Neoplasms. Cancer Research, 2010. 70(8): p. 3402-3410.
36. Massa M., V. Rosti, I. Ramajoli, R. Campanelli, A. Pecci, G. Viarengo, V. Meli, M. Marchetti, R. Hoffman, and G. Barosi, Circulating CD34+, CD133+, and Vascular Endothelial Growth Factor Receptor 2-Positive Endothelial Progenitor Cells in Myelofibrosis With Myeloid Metaplasia. Journal of Clinical Oncology, 2005. 23(24): p. 56885695.
37. Schmitt A., H. Jouault, J. Guichard, F. Wendling, A. Drouin, and E.M. Cramer, Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. Blood, 2000. 96(4): p. 1342-1347.
38. Cervantes F., A. Alvarez-Larran, C. Talarn, M. Gomez, and E. Montserrat, Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. British Journal of Haematology, 2002. 118(3): p. 786-790.
39. Passamonti F., E. Rumi, L. Arcaini, E. Boveri, C. Elena, D. Pietra, S. Boggi, C. Astori, P. Bernasconi, M. Varettoni, E. Brusamolino, C. Pascutto, and M. Lazzarino, Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica, 2008. 93(11): p. 1645-1651.
40. Wolanskyj A.P., S.M. Schwager, R.F. McClure, D.R. Larson, and A. Tefferi, Essential Thrombocythemia Beyond the First Decade: Life Expectancy, Long-term Complication Rates, and Prognostic Factors. Mayo Clinic Proceedings, 2006. 81(2): p. 159-166.
41. Kiladjian J.-J., J.-D. Rain, J.-F. Bernard, J. Briere, C. Chomienne, and P. Fenaux, Long-Term Incidence of Hematological Evolution in Three French Prospective Studies of Hydroxyurea and Pipobroman in Polycythemia Vera and Essential Thrombocythemia. Semin Thromb Hemost, 2006. 32(04): p. 417-421.
42. Passamonti F., E. Rumi, L. Arcaini, E. Boveri, C. Elena, D. Pietra, S. Boggi, C. Astori, P. Bernasconi, M. Varettoni, E. Brusamolino, C. Pascutto, and M. Lazzarino, Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica, 2008. 93(11): p. 1645-1651.
43. Tefferi, A. Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study / A.Tefferi, R.Vaidya, D.Caramazza et al. // Journal of Clinical Oncology. - 2011. - Vol.29 №10. - P.1356-1363.
44. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood 2007;110:1092-1097.
45. Mossuz P, Girodon F, Donnard M, et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica 2004;89: 1194-1198.
46. Crisa E, Venturino E, Passera R, et al. A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and nonalkylating drugs. Ann Hematol 2010;89:691-699.
47. Diehn F, Tefferi A. Pruritus in polycythaemia vera: Prevalence, laboratory correlates and management. Br J Haematol 2001;115:619-621.
48. Finazzi G, Barbui T. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia 2008;22:1494-1502.
49. Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 2012;120:5128-5133; quiz 5252.
50. Tefferi A. et.al. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.// American Journal of Hematology. 2012 (87). 285-293.
51. Barbui T, Barosi G., Birgegard G. et.al. Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet.//JCO. 2011. 29(6). 761-770.
52. Michiels JJ, Berneman Z, Schroyens W, et al. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost 2006;32:589604.].
53. Budde U, Schaefer G, Mueller N, et al. Acquired von Willebrand’s disease in the myeloproliferative syndrome. Blood 1984;64:981-985.
54. Pardanani A, Vannucchi AM, Passamonti F, Cervantes F, Barbui T, Tefferi A. JAK inhibitor therapy for myelofibrosis: Critical assessment of value and limitations. Leukemia 2011;25:218-225
55. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011;29:789-796.
56. Barbui T.et al. Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet. JCO, 2011. 29(6): p. 761-770.
57. Verstovsek S. et al. Long-Term Efficacy and Safety Results From a Phase II Study of Ruxolitinib in Patients with Polycythemia Vera. ASH Annual Meeting Abstracts, 2012. 120(21): p. 804
58. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. New Engl J Med 2013;368:22-33.
59. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114-124.
60. Pascale S, Petrucci G, Dragani A, et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 2012;119:3595-3603
61. Finazzi G. A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP). Pathol Biol (Paris) 2004;52:285-288
62. Ayalew Tefferi Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management American Journal of Hematology Volume 88, Issue 6, pages 507-516, June 2013
63. Passamonti F How I treat polycythemia vera. Blood. 2012 Jul 12;120(2):275-84. doi: 10.1182/blood-2012-02-366054. Epub 2012 May 18
64. Fruchtman SM, Mack K, Kaplan ME, Peterson P, Berk PD, Wasserman LR From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol. 1997 Jan;34(1):17-23.
65. Barosi G. et al A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. British Journal of Haematology, 2010. 148(6): p. 961-963.
66. Quintas-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009;27(32):5418-5424.
67. Kiladjian JJ, Chomienne C, Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia. 2008 Nov;22(11):1990-8. doi: 10.1038/leu.2008.280. Epub 2008 Oct 9
68. Treatment of polycythaemia vera by radiophosphorus or busulphan: A randomized trial. "Leukemia and Hematosarcoma" Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.). Br J Cancer 1981;44:75-80.
69. Barosi G, Mesa R, Finazzi G, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013 Jun 6;121(23):4778-81. doi: 10.1182/blood-2013-01-478891. Epub 2013 Apr 16.
70. Mesa R.A., M.N. Silverstein, S.J. Jacobsen, P.C. Wollan, and A. Tefferi, Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted county study, 1976-1995. American Journal of Hematology, 1999. 61(1): p. 10-15.
71. Tefferi A., L.A. Solberg, and M.N. Silverstein, A clinical update in polycythemia vera and essential thrombocythemia. The American journal of medicine, 2000. 109(2): p. 141-149.
72. Alvarez-Larran A., F. Cervantes, B. Bellosillo, et al. Essential Thrombocythemia in Young Individuals: Frequency and Risk Factors for Vascular Events and Evolution to Myelofibrosis in 126 Patients. ASH Annual Meeting Abstracts, 2006. 108(11): p. 3598-.
73. Palandri F., N. Polverelli, E. Ottaviani, F. Castagnetti, M. Baccarani, and N. Vianelli, Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients. Haematologica, 2010. 95(6): p. 1038-1040.
74. Mesa R.A., M.N. Silverstein, S.J. Jacobsen, P.C. Wollan, and A. Tefferi, Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted county study, 1976-1995. American Journal of Hematology, 1999. 61(1): p. 10-15.
75. Shuvaev V.A. Essential thrombocythemia - population analysis, a single center 10-years’experience. / V.A.Shuvaev, A.S.Abdulkadyrova, I.S.Martynkevich et al. ELN Frontiers Meeting «New Frontiers of Myeloid Neoplasias» 11-13 October, 2013, Prague, Czech Republic// ELN Information letter October 2013. - p.21
76. Thiele J, Kvasnicka HM, Vardiman JW, et al. Bone marrow fibrosis and diagnosis of essential thrombocythemia. J Clin Oncol 2009;27:e220-221; author reply e222-223.
77. Schmitt-Graeff AH, Teo SS, Olschewski M, et al. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica 2008;93:34-40.
78. Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: The 2008 WHO classification. Am J Hematol 2010;85:62-69.
79. Mesa R.A., M.N. Silverstein, S.J. Jacobsen, P.C. Wollan, and A. Tefferi, Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted county study, 1976-1995. American Journal of Hematology, 1999. 61(1): p. 10-15.
80. Alvarez-Larran A, Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood 2010;116:1205-1210; quiz 1387.
81. Michiels JJ, Berneman Z, Schroyens W, et al. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: A distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. Platelets 2006;17:528-544.
82. Michiels JJ, Abels J, Steketee J, van Vliet HH, Vuzevski VD. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Int Med 1985;102:466-471.
83. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004 Jan 8;350(2): 114-24.
84. Kayacioglu I, Gunay R, Saskin H, et al. The role of clopidogrel and acetylsalicylic acid in the prevention of early-phase graft occlusion due to reactive thrombocytosis after coronary artery bypass operation. Heart Surg Forum 2008;11:E152-E157.
85. Solberg Jr L.A., A. Tefferi, K.J. Oles, J.S. Tarach, R.M. Petitt, L.A. Forstrom, and M.N. Silverstein, The effects of anagrelide on human megakaryocytopoiesis. British Journal of Haematology, 1997. 99(1): p. 174-180.
86. Harrison C.N., P.J. Campbell, G. Buck, K. Wheatley, C.L. East, D. Bareford, B.S. Wilkins, J.D. van der Walt, J.T. Reilly, A.P. Grigg, P. Revell, B.E. Woodcock, and A.R. Green, Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia. New England Journal of Medicine, 2005. 353(1): p. 33-45.
87. Storen E.C. and A. Tefferi, Long-term use of anagrelide in young patients with essential thrombocythemia. Blood, 2001. 97(4): p. 863-866.
88. John Mascarenhasa,., Mark L. Heaneyb, Vesna Najfelda Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): Formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. Leukemia Research Volume 36, Issue 12 , Pages 1500-1504, December 2012
89. Hans Kreipe & Kais Hussein & Gudrun Gohring & Brigitte Schlegelberger Progression of myeloproliferative neoplasms to myelofibrosis and acute leukaemia J Hematopathol (2011) 4:61-68
90. Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, Dupriez B, Levine RL, Passamonti F, Gotlib J, Reilly JT, Vannucchi AM, Hanson CA, Solberg LA, Orazi A, Tefferi A; International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008 Feb;22(2):437-8. Epub 2007 Aug 30.
91. Абдулкадыров, К.М. Клиническая гематология : справочник. / К.М.Абдулкадыров. - СПб: Питер Принт, 2006. - 843с.
92. Абдулкадыров, К.М. Хронический лейкоз-ретикулоз (некоторые вопросы патогенеза, клиники и лечения). Автореф.дисс.док.мед.наук. / К.М.Абдулкадыров. - Л., 1973. - 73с.
93. Воробьев, А.И. Руководство по гематологии / А.И.Воробьев. - М.: Ньюдиамед, 2003. - С.9-15.
94. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, Bogani C, Ferrini PR, Rambaldi A, Guerini V, Bosi A, Barbui T; MPD Research Consortium. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia. 2007 Sep;21(9):1952-9. Epub 2007 Jul 12.
95. Tefferi A., Huang J., Schwager S. et al. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Cancer 2007; 109: 2083-8.
96. Абдулкадыров К.М. Критерии диагностики и современные методы лечения первичного миелофиброза / К.М.Абдулкадыров, В.А.Шуваев, И.С.Мартынкевич // Вестник Гематологии.- 2013.- Т.9.- №3. С.44-78
97. Strasser-Weippl K, Steurer M, Kees M, Augustin F, Tzankov A, Dirnhofer S, Fiegl M, Simonitsch-Klupp I, Zojer N, Gisslinger H, Ludwig H. Age and hemoglobin level emerge as most important clinical prognostic parameters in patients with osteomyelofibrosis: introduction of a simplified prognostic score. Leuk Lymphoma. 2006 Mar;47(3):441-50.
98. Cervantes, F. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment / F.Cervantes, B.Dupriez, A.Pereira et al. // Blood. -2009. - Vol.113 №13. - P.2895-2901.
99. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Cazzola M, Tefferi ADynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia inprimary myelofibrosis. Blood. 2010 Oct 14;116(15):2857-8. doi: 10.1182/blood-2010-06-293415.
100. Cervantes F, Alvarez-Larran A, Domingo A, Arellano-Rodrigo E, Montserrat E. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol. 2005 Jun;129(6):771-5.
101. Martmez-Trillos A, Gaya A, Maffioli M, Arellano-Rodrigo E, Calvo X. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol. 2010 Dec;89(12):1233-7. doi: 10.1007/s00277-010-1019-9. Epub 2010 Jun 22.
102. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR;United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45.
103. Ianotto JC, Kiladjian JJ, Demory JL, Roy L, Boyer F, Rey J, Dupriez B, Berthou C, Abgrall JF. PEG-IFN-alpha-2a therapy in patients with myelofibrosis: a study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myeloproliferatifs (FIM). Br J Haematol. 2009 Jul;146(2):223-5. doi: 10.1111/j.1365-2141.2009.07745.x. Epub 2009 May 26.
104. Guglielmelli P, Barosi G, Specchia G, Rambaldi A, Lo Coco F, Antonioli E, Pieri L, Pancrazzi A, Ponziani V, Delaini F, Longo G, Ammatuna E, Liso V, Bosi A,Barbui T, Vannucchi AM. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood. 2009 Aug 20;114(8):1477-83. doi: 10.1182/blood-2009-04-216044. Epub 2009 Jun 23.
105. Gangat, N. DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status / N.Gangat, D.Caramazza, R.Vaidya et al. // Journal of Clinical Oncology. - 2011. - Vol.29 №4. P.392-397.
106. Gangat N. et.al., DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status, JCO, 2010 Vol 29, N 4, pp 392-397
107. Ditschkowski M. et.al. Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis, Haematologica 2012;97(10):1574-1581.
108. Barbui T. et.al. Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet, JCO 2011 Vol 29, N 6, pp 761-770
109. Kroger N. et.al., Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation, Blood 2009 114: 5264-5270
110. Ballen K., How to manage the transplant question in myelofibrosis, Blood Cancer Journal, 2012 2, e59 doi:10.1038/bcj.2012.3
111. Kennedy J. A et.al., Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms, Blood, 2013 121: 2725-2733
112. Barosi, G. Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET) / G.Barosi, D.Bordessoule, J.Briere et al. // Blood. - 2005. - Vol.106 №8. -P.2849-53.
113. Huang, J. Erythropoiesis Stimulating Agents and the Risk of Leukemic Transformation in Primary Myelofibrosis / J.Huang, C.-Y.Li, R.A.Mesa et al. // ASH Annual Meeting Abstracts. - 2007. - Vol.110 №11. - P.554.
114. Barosi, G. Therapeutic approaches in myelofibrosis / G.Barosi, V.Rosti, A.M.Vannucchi // Expert Opinion on Pharmacotherapy. - 2011. - Vol.12 №(10). - P.1597-1611. Tefferi, A. How I treat myelofibrosis / A.Tefferi // Blood. - 2011. - Vol.117 №13. - P.3494-3504.

115 .Cervantes, F. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature / F.Cervantes, A.Alvarez-Larran, J.-C.Hernandez-Boluda et al. // British Journal of Haematology. - 2004. - Vol.127 №4. - P.399-403.
116 .Mesa, R.A. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia/ R.A.Mesa, D.P.Steensma, A.Pardanani et al. // Blood. - 2003. - Vol.101 №7. - P.25342541.
117 .Mesa, R.A. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903 / R.A.Mesa, X.Yao, L.D.Cripe et al. // Blood. - 2010. - Vol.116 №22. - P.4436-4438.
118 .Quintas-Cardama, A. Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis / A.Quintas-Cardama, H.M.Kantarjian, T.Manshouri et al. // Journal of Clinical Oncology. - 2009. - Vol.27 №28. - P.4760-4766.
119 .Quintas-Cardama, A. Phase II Study of Lenalidomide and Prednisone for Patients with Myelofibrosis / A.Quintas-Cardama, A.Tefferi, D.Thomas et al. // ASH Annual Meeting Abstracts. - 2007. Vol.110 №11. P.3545.
120 .Besa, E.C. Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: The value of chromosomal studies in predicting response and survival / E.C.Besa, P.C.Nowell, N.L.Geller, F.H.Gardner // Cancer. - 1982. Vol.49 №2. - P.308-313.
121 .Branda, R.A. Randomized Study of Nandrolone Therapy for Anemias Due to Bone Marrow Failure / R.A.Branda, T.W.Amsden, H.S.Jacob // Arch Intern Med. - 1977. - Vol.137 №1. - P.5.

122 .Cervantes F, Alvarez-Larran A, Domingo A, Arellano-Rodrigo E, Montserrat E. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol. 2005 Jun;129(6):771-5.
123 .Quintas-Cardama, A Spleen deflation and beyond: The pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms / A.Quintas-Cardama, S. Verstovsek // Cancer. - 2012. Vol.118 №4. -P.870-877.
124 .Mesa, R.A. Associations Between Improvements in Myelofibrosis (MF) Symptoms and Quality of Life Measures with Splenomegaly Reduction in COMFORT-I: A Randomized, Double-Blind, Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib Versus Placebo in Patients with MF / R.A.Mesa, J.Gotlib, V.Gupta et al. // ASH Annual Meeting Abstracts. - 2011. - Vol.118 №21. - P.3842.
125 .Verstovsek, S. Adverse events (AEs) and the return of myelofibrosis (MF)-related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy / S.Verstovsek, R.A.Mesa, J.R.Gotlib et al. // Journal of Clinical Oncology. - 2012. Vol.30 №15_suppl (May 20 Supplement). - P.6624.
126 .Verstovsek, S. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls / S.Verstovsek, H.M.Kantarjian, Z.Estrov et al. // Blood. - 2012. - Vol.120 №6. - P.1202-1209.
127 .Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood. 2000 Apr 1;95(7):2226-33.
128 .Feldman LS, Demyttenaere SV, Polyhronopoulos GN, Fried GM. Refining the selection criteria for laparoscopic versus open splenectomy for splenomegaly. J Laparoendosc Adv Surg Tech A. 2008 Feb;18(1):13-9. doi: 10.1089/lap.2007.0050.
129 .Faoro LN, Tefferi A, Mesa RA. Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia. Eur J Haematol. 2005 Feb;74(2): 117-20.
130 .Mesa, R.A. How I treat symptomatic splenomegaly in patients with myelofibrosis / R.A.Mesa // Blood. - 2009. -Vol.113 №22. - P.5394-5400.
131 .А. Л. Меликян Л. Ю. Колосова М. А. Соколова А. М. Ковригина М. А. Силаев Е. А. Гилязитдинова Э. Г. Гемджян С. Р. Карагюлян. Роль спленэктомии при лечении больных миелофиброзом. Тер. архив. 2013 №8 с. 69-76.
132 .A.L. Melikyan, Kovrigina А.М., Sokolova M.A., Kolosova L.U., Silaev M.A., Gilyazitdinova E.A., Subortseva I.N., Gemdjian E.G., Karagulyan S.R, Savchenko V.G. The Role Of Splenectomy In The Treatment Of Myelofibrosis Blood 2013.
133 .Alvarez-Larran A, Abraldes JG, Cervantes F, Hernandez-Guerra M Portal hypertension secondary to myelofibrosis: a study of three cases. Am J Gastroenterol. 2005 Oct;100(10):2355-8.
134 .Doki N, Irisawa H, Takada S, Sakura T, Miyawaki S. Transjugular intrahepatic portosystemic shunt for the treatment of portal hypertension due to idiopathic myelofibrosis. Intern Med. 2007;46(4):187-90. Epub 2007 Feb 15.
135 .Barosi G, Ambrosetti A, Buratti A, Finelli C, Liberato NL, Quaglini S, Ricetti MM.Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction. Leukemia. 1993 Feb;7(2):200-6.

136 .Harrison, C. N. Results of a randomized study of the JAK inhibitor INC424 compared with best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF) / C.N.Harrison, J.Kiladjan, H.K.Al-Ali et al. // Journal of Clinical Oncology. - 2011. - Vol.29 №15_suppl (May 20 Supplement). - P.LBA6501.
137 .Verstovsek, S. Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I / S.Verstovsek, R.A.Mesa, J.Gotlib et al. // ASH Annual Meeting Abstracts. - 2011. - Vol.118 №21. - P. 278.
138 .Baden, L.R. Prophylactic Antimicrobial Agents and the Importance of Fitness. / L.R.Baden // New England Journal of Medicine. - 2005. - Vol.353 №10. - P.1052-1054.
139 . Cullen, M. Antibacterial Prophylaxis after Chemotherapy for Solid Tumors and Lymphomas / M.Cullen, N.Steven, L.Billingham et al. // New England Journal of Medicine. - 2005. - Vol.353 №10. - P.988-998.
140 .Elliott, M.A. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia / M.A.Elliott, M.G.Chen, M.N.Silverstein et al. // British Journal of Haematology,. - 1998. - Vol.103 №2. - P.505-511.
141 .Elting, L.S. Outcomes of Bacteremia in Patients with Cancer and Neutropenia: Observations from Two Decades of Epidemiological and Clinical Trials / L.S.Elting, E.B.Rubenstein, E.B.Rolston et al // Clinical Infectious Diseases. - 1997. - Vol.25(2). - P.247-259.
142 .Freifeld A., D. Marchigiani, T. Walsh, S. Chanock, L. Lewis, J. Hiemenz, S. Hiemenz, J.E. Hicks, V. Gill, S.M. Steinberg, and P.A. Pizzo, A Double-Blind Comparison of Empirical Oral and Intravenous Antibiotic Therapy for Low-Risk Febrile Patients with Neutropenia during Cancer Chemotherapy. New England Journal of Medicine, 1999. 341(5): p. 305-311.
143 .Gilbert, D. The Sanford guide to antimicrobial therapy/ D.N Gilbert, R.C.Moellering, // VT: Sanford Publishers Hyde Park, 2007. - 358p.
144 .Boogaerts, M. Intravenous and Oral Itraconazole versus Intravenous Amphotericin B Deoxycholate as Empirical Antifungal Therapy for Persistent Fever in Neutropenic Patients with Cancer Who Are Receiving Broad-Spectrum Antibacterial Therapy A Randomized, Controlled Trial / M.Boogaerts, D.J.Winston, E.J.Bow et al. // Annals of Internal Medicine. - 2001. - Vol.135 №6. - P.412-422.
145 .Wade, J.C. Intravenous Acyclovir to Treat Mucocutaneous Herpes Simplex Virus Infection After Marrow Transplantation A Double-Blind Trial / J.C.Wade, B.Newton, C.McLaren et al. // Annals of Internal Medicine. -1982. - Vol.96 №3. - P.265-269.
146 .Smith, T.J. 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An EvidenceBased Clinical Practice Guideline / T.J.Smith, J.Khatcheressian, G.H.Lyman et al. // Journal of Clinical Oncology. - 2006. - Vol.24 №19. - P.3187-3205.
147 .Harrison, C. N. Results of a randomized study of the JAK inhibitor INC424 compared with best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF) / C.N.Harrison, J.Kiladjan, H.K.Al-Ali et al. // Journal of Clinical Oncology. - 2011. - Vol.29 №15_suppl (May 20 Supplement). - P.LBA6501.
148 .Verstovsek, S. Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I / S.Verstovsek.
149 .Cho, S.Y. The Effect of CXCL12 Processing on CD34+ Cell Migration in Myeloproliferative Neoplasms / S.Y.Cho, M.Xu, J.Roboz et al. // Cancer Research. - 2010. - Vol.70 №8. P.3402-3410.
150 .Massa, M. Circulating CD34+, CD133+, and Vascular Endothelial Growth Factor Receptor 2-Positive Endothelial Progenitor Cells in Myelofibrosis With Myeloid Metaplasia / M.Massa, V.Rosti, I.Ramajoli et al. // Journal of Clinical Oncology. - 2005. - Vol.23 №24. - P.5688-5695.
151 .Koch, C.A. Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment / C.A.Koch, C.Y.Li, R.A.Mesa // Mayo Clin Proc. - 2003. - Vol.78. - P.1223-1233.
152 .Neben-Wittich, M.A. Successful treatment of severe extremity pain in myelofibrosis with low-dose single-fraction radiation therapy / M.A.Neben-Wittich, P.D.Brown, A.Tefferi // American Journal of Hematology. - 2010. -Vol.85 №10. - P.808-810.
153 .Steensma, D.P. Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia / D.P.Steensma, C.C.Hook, S.L.Stafford et al. // British Journal of Haematology. - 2002. - Vol.118 №3. - P.813-816.
154 .Kwiatkowski, J.L. Management of transfusional iron overload - differential properties and efficacy of iron chelating agents. / J.L.Kwiatkowski // J Blood Med. - 2011. - №2. - P.135-49.
155 .Ayalew Tefferi,1 Francisco Cervantes,2 Ruben Mesa, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report.
156 .Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD.The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009 Jul 30;114(5):937-51. doi: 10.1182/blood-2009-03-209262. Epub 2009 Apr 8.
157 .Barbui, T. Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet / T.Barbui, G. Barosi, G. Birgegard et l. // Journal of Clinical Oncology. - 2011. - Vol.29 №6. - P.761-770.
158 .Fenaux, P. Clinical course of essential thrombocythemia in 147 cases / P.Fenaux, M. Simon, M.T. Caulier, et al. // Cancer. - 1990. - Vol.66 №3. - P.549-556.
159 .Barbui, T. Thrombosis in primary myelofibrosis: incidence and risk factors / T.Barbui, A.Carobbio, F.Cervantes et al. // Blood. - 2010. - Vol.115 №4. - P.778-782.

Для продолжения работы требуется Регистрация

Предыдущая страница

Следующая страница